Bronchiectasis Clinical Trials

What Has Gone Wrong in the Airways

Your airways are meant to be smooth springy tubes that narrow neatly as they branch deeper into the lung. Here, some of those tubes have been stretched wide and scarred for good, usually by an infection or a long stretch of inflammation. So widened floppy airways cannot sweep mucus out the way healthy ones do.

The Circle That Keeps It Going

This is the clearest way to picture the disease. Mucus pools, so bacteria settle in and multiply. The immune system attacks them, and the fight damages the airway further. The airway widens more, so more mucus pools. Round and round it goes. Meanwhile, every treatment either tries to break the mucus half of that circle or the inflammation half.

What a Flare Costs You

Day to day this means a wet cough most days, phlegm, breathlessness, tiredness and repeated chest infections. Then it flares. More phlegm, a change in its colour, more breathlessness, usually antibiotics and sometimes hospital. Notably, each flare tends to leave lung function slightly worse than before. So preventing flares, rather than treating them, is the whole point of modern treatment.

The Two Bugs That Change the Conversation

Pseudomonas is the one doctors most dread. Once it settles in permanently it is very hard to shift, and people who carry it flare more often and do worse over time. NTM is the other, a slow growing relative of the TB germ. Also, active NTM rules you out of both studies here, so it is worth knowing your status before you call.

Nothing Was Ever Approved for It

Until last year there was no approved drug for this condition at all. Everything in use was either supportive, such as physiotherapy and salt water mists, or borrowed off label from other diseases. So doctors were managing a common, progressive, damaging condition with nothing written for it.

That Changed on 12 August 2025

A drug called brensocatib was approved for people aged 12 and over, the first therapy ever approved for this. Rather than killing bacteria, it turns down the destructive enzymes released by immune cells. As James Chalmers of the University of Dundee put it, it is the first treatment that targets the kind of inflammation that drives a lot of flares. In its main trial, it cut flares by roughly 20 percent against a dummy.

What That Did to Research Here

It turned a neglected disease into a serious field almost overnight. Doreen Addrizzo-Harris of NYU called the approval a potential shift in how this condition is approached. Both studies here are large drug company programmes, one from AstraZeneca and one from GSK. However, that new drug also created a new gate, because starting it in the past 3 months rules you out of one of them.